Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $2,090,500.00 in Stock

Key Points

• CEO Lawrence Klein sold 25,000 Oruka Therapeutics shares at an average price of $83.62, generating $2.09 million. The Rule 10b5-1 transaction reduced his holdings by 2.64% to 923,128 shares.
• Oruka shares rose 1.3% to $84.52, but the company recently reported a quarterly EPS loss of $0.55, missing analysts’ $0.51-loss estimate.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $128.91 target price; institutional investors own 56.44% of the stock.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) CEO Lawrence Klein sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $83.62, for a total value of $2,090,500.00. Following the transaction, the chief executive officer owned 923,128 shares in the company, valued at $77,191,963.36. The trade was a 2.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence Otto Klein also recently made the following trade(s):

• On Tuesday, September 15th, Lawrence Klein sold 2,452 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total value of $234,680.92.
• On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00.

Oruka Therapeutics Stock Up 1.3%

Shares of Oruka Therapeutics stock traded up $1.10 during trading on Friday, reaching $84.52. The company's stock had a trading volume of 581,494 shares, compared to its average volume of 969,009. Oruka Therapeutics, Inc. has a 12-month low of $19.04 and a 12-month high of $115.51. The business has a 50 day moving average price of $95.77 and a 200-day moving average price of $77.45.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Weiss Ratings upgraded shares of Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 15th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. UBS Group upped their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. Wedbush set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, September 24th. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $128.91.

Institutional Trading of Oruka Therapeutics

Large investors have recently bought and sold shares of the company. Nykredit A S purchased a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $29,000. Orion Capital Management LLC purchased a new position in Oruka Therapeutics during the 2nd quarter valued at about $91,000. Natural Investments LLC purchased a new position in Oruka Therapeutics during the 2nd quarter valued at about $202,000. Caitong International Asset Management Co. Ltd purchased a new position in Oruka Therapeutics during the 4th quarter valued at about $67,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Oruka Therapeutics during the second quarter worth about $211,000. Institutional investors and hedge funds own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc NASDAQ: ORKA is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company's approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka's pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.